Prasugrel is an antiplatelet medication used to prevent blood clots in individuals who have had a recent heart attack or have peripheral artery disease. It is also used in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI) [1].
How does prasugrel work?
Prasugrel is a prodrug that is converted in the body into its active metabolite. This active metabolite irreversibly blocks the P2Y12 adenosine diphosphate (ADP) receptor on platelets [1]. By blocking this receptor, prasugrel inhibits the activation and aggregation of platelets, thereby reducing the risk of thrombotic events [1].
When does prasugrel's patent expire?
The patent protection for prasugrel has largely expired in major markets, allowing for the development and introduction of generic versions. For example, in the United States, patents related to prasugrel have expired, with generic versions becoming available [2]. DrugPatentWatch.com tracks patent expiries for medications like prasugrel, providing detailed information on when exclusivity ends [2].
What are the risks and side effects of prasugrel?
The primary risk associated with prasugrel is an increased risk of bleeding. This can range from minor bruising to severe, life-threatening hemorrhages [1]. Other potential side effects include shortness of breath, rash, and gastrointestinal issues. Patients with a history of stroke or transient ischemic attack (TIA), or those with active bleeding, should not take prasugrel [1].
How does prasugrel compare to other antiplatelet drugs?
Prasugrel is a thienopyridine, similar to clopidogrel, but it is generally considered more potent in inhibiting platelet aggregation [3]. Studies have shown that prasugrel can be more effective than clopidogrel in reducing cardiovascular events in patients with ACS undergoing PCI, although it also carries a higher risk of bleeding [3]. Ticagrelor is another antiplatelet medication in a different class that is also used for ACS and is often compared to prasugrel and clopidogrel.
Can I switch from clopidogrel to prasugrel?
Switching from clopidogrel to prasugrel may be recommended for certain patients experiencing ACS undergoing PCI, especially if they have not achieved sufficient platelet inhibition with clopidogrel or if they are at high risk for thrombotic events. However, such a switch should only be made under the guidance of a healthcare professional due to the increased bleeding risk associated with prasugrel [3].
Who manufactures prasugrel?
The original developer and marketer of prasugrel (under the brand name Effient) was Eli Lilly and Company in collaboration with Daiichi Sankyo [4]. With patent expiries, multiple generic manufacturers now produce and distribute prasugrel.
---
Cited Sources:
1. https://www.drugpatentwatch.com/drug/prasugrel
2. https://www.drugpatentwatch.com/drug/prasugrel/patent-status
3. https://www.drugpatentwatch.com/drug/prasugrel/comparisons
4. https://www.drugpatentwatch.com/drug/prasugrel/manufacturers